Augmedix vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco medical documentation company combining AI transcription with remote human scribes to produce EHR notes from physician-patient encounters in real time via smartphone or Glass.
About
Augmedix is a San Francisco-based medical documentation company that combines AI transcription technology with remote human scribes to document physician-patient encounters in real time, producing complete EHR notes that physicians review and sign. Physicians wear Google Glass or use a smartphone to stream audio and video of patient encounters to Augmedix's platform, where remote scribes observe and document the visit, supported by AI tools that transcribe speech and suggest note structures. This hybrid AI-plus-human model enables documentation quality and customization that pure AI solutions struggle to achieve for complex clinical encounters, while still dramatically reducing the time physicians spend on documentation. Augmedix serves large health systems and multispecialty groups, with customer deployments across hundreds of physicians. The company went public via merger with LifeSci Acquisition in 2020 and was subsequently acquired by Nuvation Bio. Augmedix competes with Nuance DAX, Suki, and traditional medical transcription services in the clinical documentation market.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.